Alnylam Pharmaceuticals (ALNY) Long-Term Investments (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Long-Term Investments for 18 consecutive years, with $22.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Long-Term Investments fell 67.68% year-over-year to $22.2 million; the trailing twelve-month figure through Jun 2026 stood at $22.2 million (down 67.68% YoY), and the FY2025 full-year result was $22.2 million, down 67.68% from the prior year.
• Long-Term Investments was little changed at $22.2 million in Q2 2026 per ALNY's latest filing, from $22.2 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $68.6 million in Q4 2024 and bottomed at $22.2 million in Q4 2025.
• Historically, Long-Term Investments has averaged $48.8 million across 5 years, with a median of $49.4 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Long-Term Investments jumped 38.88% in 2024, then tumbled 67.68% in 2025.
• Over 5 years, Long-Term Investments stood at $49.4 million in 2022, then rose by 0.0% to $49.4 million in 2023, then surged by 38.88% to $68.6 million in 2024, then sank by 67.68% to $22.2 million in 2025, then gained by 0.0% to $22.2 million in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered $22.2 million, $22.2 million, and $22.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.